Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea
January 13 2022 - 6:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immunotherapeutics for the prevention and treatment of gut
mediated pathogens, is pleased to announce that it has been granted
a European Patent for compositions and methods for treating
travelers’ diarrhea.
European Patent 3159357, entitled “Composition
and method for the treatment and prevention of enteric bacterial
infections”, was granted on January 5, 2022.
Immuron is validating the patent in the
following European member states, France, Spain, Sweden, Austria,
Germany, Denmark, Finland, Greece and United Kingdom. The European
registration adds to Immuron's patent position for compositions and
methods for treating travelers’ diarrhea in Australia, India,
Canada and the Unites States.
Infectious diarrhea is the most common illness
reported by travelers visiting developing countries and among US
troops deployed overseas. The morbidity and associated discomfort
stemming from diarrhea decreases daily performance, affects
judgment, decreases morale, and declines operational readiness. The
first line of treatment for infectious diarrhea is the prescription
of antibiotics. Unfortunately, in the last decade, several enteric
pathogens have an increasing resistance to commonly prescribed
antibiotics. In addition, travelers' diarrhea is now recognized by
the medical community to result in post-infectious sequelae,
including post-infectious irritable bowel syndrome and several
post-infectious autoimmune diseases. A preventative treatment that
protects against enteric diseases is a high priority objective for
the US Military.
This release has been authorised by the
directors of Immuron Limited.
COMPANY
CONTACT:Dr Jerry
Kanellos, Ph.D.Chief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
US INVESTOR CONTACTDave Gentry,
CEORedChip Companies
Inc.+1-407-491-4498dave@redchip.com |
|
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of infectious
diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024